International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 931–940 | Cite as

Role of clinical pharmacist in the management of blood pressure in dialysis patients

  • Bonyan Qudah
  • Abla Albsoul-YounesEmail author
  • Ezat Alawa
  • Nabil Mehyar
Research Article


Background Hypertension is highly prevalent yet undertreated condition in hemodialysis patients. Objective The objective of this study was to evaluate clinical pharmacist’s role in the management of blood pressure in hemodialysis patients guided by home blood pressure monitoring. Setting Outpatient hemodialysis units of Jordan University Hospital and Isra’a Hospital. Method This was a randomized controlled study. It lasted 6 months (September 2011 till the end of March 2012). All hypertensive patients receiving hemodialysis were invited to participate in the study. Out of 60 patients approached, 56 were actually included. Patients were randomly allocated to an intervention (29) or control group (27). In the intervention arm, patients received physician-pharmacist collaborative care. While in the control arm patients received standard medical care. Main outcome measure Percentage of patients achieving weekly average home blood pressure below or equal 135/85 mmHg. Other secondary measures that were assessed include absolute reduction in peridialysis blood pressure, interdialytic weight gain, adherence to medications and dialysis sessions. Results A total of 52 patients completed the study. Forty-six percent of patients in the intervention arm achieved BP target (mean home blood pressure ≤135/85 mmHg) compared to only 14.3 % of patients in the control arm (p = 0.02). Average decline in weekly mean home systolic blood pressure was 10.9 ± 17.7 mmHg in the intervention arm (p = 0.004), while weekly mean home systolic blood pressure increased by 3.5 ± 18.4 mmHg in the control arm (p = 0.396). No significant reduction was achieved in weekly home diastolic blood pressure, dialysis blood pressure readings, or interdialytic weight gain in either arm. Conclusions Clinical pharmacist-physicians’ collaboration improved rate of blood pressure control in hemodialysis patients. Using home blood pressure monitoring was found to be an efficient way to guide blood pressure therapy.


Pharmaceutical care Hypertension Dialysis Jordan 



Special thanks to hemodialysis patients who participated in the study and committed through and staff nurses in the dialysis unit of Jordan University Hospital and Isra’a Hospital for their assistance and cooperation.


This study was supported by the Deanship of research, The University of Jordan.

Conflicts of interest

The authors have no conflict to declare.


  1. 1.
    Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010;55(3):762–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dzgoeva FU, Gatagonova TM, Kadzaeva ZK, Khamitsaeva OV, Kochisova ZK, Dzutseva AT, et al. Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension. Terapevticheskii Arkhiv. 2011;83(6):42–6.PubMedGoogle Scholar
  4. 4.
    Campese VM, Vidhun J, Park J. Hypertension in Dialysis Patients. In: Henrich William L, editor. Principles and practice of dialysis. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 289–316.Google Scholar
  5. 5.
    Da Silva GV, de Barros S, Abensur H, Ortega KC, Mion D Jr. Cochrane renal group prospective trial register: CRG060800146. Home blood pressure monitoring in blood pressure control among haemodialysis patients: an open randomized clinical trial. Nephrol Dial Transpl. 2009;24(12):3805–11.CrossRefGoogle Scholar
  6. 6.
    Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saha C. Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension. 2006;47(1):62–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Moriya H, Oka M, Maesato K, Mano T, Ikee R, Ohtake T, et al. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. Clin J Am Soc Nephrol. 2008;3(2):416–22. doi: 10.2215/CJN.03490807.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2(6):1228–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Agarwal R, Sinha AD, Light RP. Toward a definition of masked hypertension and white coat hypertension among hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(8):2003–8. doi: 10.2215/CJN.02700311.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, et al. Medication prescribing patterns in ambulatory hemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transpl. 2004;19(7):1842–8.CrossRefGoogle Scholar
  11. 11.
    Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12:35. doi: 10.1186/1471-2369-12-35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists’ interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transpl. 2012;27(1):276–92.CrossRefGoogle Scholar
  13. 13.
    Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bonso E, Dorigatti F, Palatini P. Accuracy of the BP A100 blood pressure measuring device coupled with a single cuff with standard-size bladder over a wide range of arm circumferences. Blood Press Monit. 2009;14(5):216–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Agarwal R, Lewis R. Prediction of hypertension in chronic hemodialysis patients. Kidney Int. 2001;60:1982–9.CrossRefPubMedGoogle Scholar
  16. 16.
    K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1–153.Google Scholar
  17. 17.
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. Am J Health Syst Pharm. 2011;68(3):241–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Albsoul-Younes AM, Hammad EA, Yasein NA, Tahaineh LM. Pharmacist-physician collaboration improves blood pressure control. Saudi Med J. 2011;32(3):288–92.PubMedGoogle Scholar
  20. 20.
    Hammad EA, Yasein N, Tahaineh L, Albsoul-Younes AM. A randomized controlled trial to assess pharmacist- physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan. J Manag Care Pharm. 2011;17(4):295–303.PubMedGoogle Scholar
  21. 21.
    Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):1384–9.CrossRefPubMedGoogle Scholar
  22. 22.
    St Peter WL, Farley TM, Carter BL. Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. Curr Opin Nephrol Hypertens. 2011;20(5):498–503.CrossRefPubMedGoogle Scholar
  23. 23.
    El Borolossy R, El Wakeel L, El Hakim I, Badary O. Implementation of clinical pharmacy services in a pediatric dialysis unit. Pediatr Nephrol. 2014;29(7):1259–64. doi: 10.1007/s00467-014-2760-4.CrossRefPubMedGoogle Scholar
  24. 24.
    Machado M, Bajcar J, Guzzo GC. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41:1770–81.CrossRefPubMedGoogle Scholar
  25. 25.
    López-Gómez JM, Villaverde M, Jofre R, Rodriguez-Benítez P, Pérez-García R. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int Suppl. 2005;93:S63–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Inrig JK, Patel UD, Gillespie BS, Hasselblad V, Himmelfarb J, Reddan D, et al. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis. 2007;50(1):108–18.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Bonyan Qudah
    • 1
  • Abla Albsoul-Younes
    • 1
    • 4
    • 5
    Email author
  • Ezat Alawa
    • 2
  • Nabil Mehyar
    • 3
  1. 1.Department of Biopharmaceutics and Clinical Pharmacy, Faculty of PharmacyUniversity of JordanAmmanJordan
  2. 2.Department of Internal Medicine, Faculty of MedicineUniversity of JordanAmmanJordan
  3. 3.Division of Nephrology and Internal MedicineIsra’a HospitalAmmanJordan
  4. 4.Hamdi Mango Center for Scientific ResearchAmmanJordan
  5. 5.Chair, Pharmaceutical Care SectionUniversity of Jordan HospitalAmmanJordan

Personalised recommendations